Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Authors:
- Tsvetalina TankovaTTTsvetalina Tankova
- Elżbieta SenkusESElżbieta Senkus
- Maria BeloyartsevaMBMaria Beloyartseva
- Simona BorštnarSBSimona Borštnar
- Doina CatrinoiuDCDoina Catrinoiu
- Mona FrolovaMFMona Frolova
- Alinta HegmaneAHAlinta Hegmane
- Andrej JanežAndrej Janež
- Mladen KrnićMKMladen Krnić
- Zoltan LengyelZLZoltan Lengyel
- Yiola MarcouYMYiola Marcou
- Laura MaziluLMLaura Mazilu
Open Access
Abstract
Alpelisib is an α-selective phosphatidylinositol 3-kinase inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression on or after endocrine therapy. Hyperglycemia is an on-target effect of alpelisib affecting approximately 60% of treated patients, and sometimes necessitating dose reductions, treatment interruptions, or discontinuation of alpelisib. Early detection of hyperglycemia and timely intervention have a key role in achieving optimal glycemic control and maintaining alpelisib dose intensity to optimize the benefit of this drug. A glycemic support program implemented by an endocrinology–oncology collaborative team may be very useful in this regard. Lifestyle modifications, mainly comprising a reduced-carbohydrate diet, and a designated stepwise, personalized antihyperglycemic regimen, based on metformin, sodium–glucose co-transporter 2 inhibitors, and pioglitazone, are the main tools required to address the insulin-resistant hyperglycemia induced by alpelisib. In this report, based on the consensus of 14 oncologists and seven endocrinologists, we provide guidance for hyperglycemia management strategies before, during, and after alpelisib therapy for HR+, HER2–, PIK3CA-mutated breast cancer, with a focus on a proactive, multidisciplinary approach.Keywords
Funding Information
- Novartis (Switzerland) (not applicable)
This publication has 56 references indexed in Scilit:
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancerThe Lancet, 2017
- 5. Prevention or Delay of Type 2 DiabetesDiabetes Care, 2014
- Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical TrialsMolecular Cancer Therapeutics, 2014
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR PathwayJournal of Clinical Oncology, 2012
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast CancerJournal of Clinical Oncology, 2011
- Metformin and pioglitazone: effectively treating insulin resistanceCurrent Medical Research and Opinion, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and CancerAnnual Review of Cell and Developmental Biology, 2001